Ryan Haumschild, PharmD, MS, MBA: Welcome to this AJMC ® [The American Journal of Managed Care ®] program titled, “Generalized Pustular Psoriasis: Provider and Payer Considerations for Care.” I am Dr ...

Aaron Farberg, MD, and Mark G. Lebwohl, MD, discuss the relapsing nature of generalized pustular psoriasis and how the difficulty in diagnosing the disease affects outcomes for patients. Ryan ...

Please provide your email address to receive an email when new articles are posted on . Imsidolimab yielded a response rate of 75% at 16 weeks in patients with generalized pustular psoriasis. No ...

Please provide your email address to receive an email when new articles are posted on . The mean annualized flare rate per patient per year was 0.91, with a mean time of 5.9 months between flares.

INGELHEIM, Germany--(BUSINESS WIRE)--EFFISAYIL ™ 2 met its primary and key secondary endpoint, demonstrating that spesolimab, an anti-interleukin-36 receptor antibody, can prevent flares in ...

You’ve probably heard of psoriasis—the chronic inflammatory condition that can cause itchy, scaly patches on your skin. Less well-known is a rare form of the disease called pustular psoriasis, which ...

An international consensus statement on generalized pustular psoriasis (GPP) from the International Psoriasis Council (IPC) includes the recommendation that considerations such as body surface area ...

The US Food and Drug Administration (FDA) has approved the biologic agent spesolimab (Spevigo) for the treatment of flares in adults with generalized pustular psoriasis (GPP), the company has ...

New top-line data from a global Phase 3 clinical trial of patients with generalized pustular psoriasis (GPP) flares show rapid clearance of pustulation, erythema and scaling through four weeks after a ...

An international panel of more than 30 experts has developed a consensus definition and diagnostic criteria for generalized pustular psoriasis (GPP). The new definition, published in JAMA Dermatology, ...

BRACKNELL, England--(BUSINESS WIRE)--Boehringer Ingelheim announced today the publication in the New England Journal of Medicine of new data from the pivotal Phase II Effisayil TM 1 trial, which ...

Pustular psoriasis is characterized by clearly defined, raised pus-filled blisters, that cover large swatches of skin and is sometimes accompanied by fever, chills and severe itching. This form of ...